References

Cosmetic Prescribing Information.. 2017;

Carruthers J, Carruthers A. Using botulinum toxins cosmetically., 1st edn. London, UK: Martin Dunitz; 2003a

Carruthers J., Carruthers A. Aesthetic botulinum A toxin in the mid and lower face and neck.. Dermatol Surg.. 2003b; 29:(5)468-476 https://doi.org/10.1046/j.1524-4725.2003.29115.x

Carruthers J, Fagien S, Matarasso SL. Consensus recommendations on the use of botulinum toxin type a in facial aesthetics.. Plast Reconstr Surg.. 2004; 114:(6)1-22s https://doi.org/10.1097/01.prs.0000144795.76040.d3

Dinker S, Anitha A, Sorake A, Kumar K. Management of gummy smile with botulinum toxin type-A: a case report.. J Int Oral Health.. 2014; 6:(1)111-115

Fagien S, Carruthers JD. A comprehensive review of patient-reported satisfaction with botulinum toxin type a for aesthetic procedures.. Plast Reconstr Surg.. 2008; 122:(6)1915-1925 https://doi.org/10.1097/prs.0b013e31818dbfe3

Foster KA. Overview and history of botulinum neurotoxin clinical exploitation.. In: Foster KA (ed). New York (US): Springer; 2014

Gart M, Gutowski KA. Overview of botulinum toxins for aesthetic uses.. Clin Plast Surg.. 2016; 43:(3)459-471 https://doi.org/10.1016/j.cps.2016.03.003

Ghalamkarpour F, Robati RM, Aryanejad F, Toossi P. Supraciliary wrinkles and botulinum toxin A.. Clin Exp Dermatol.. 2010; 35:(4)388-391 https://doi.org/10.1111/j.1365-2230.2009.03607.x

Hur MS, Kim HJ, Choi BY, Hu KS, Kim HJ, Lee KS. Morphology of the mentalis muscle and its relationship with the orbicularis oris and incisivus labii inferioris muscles.. J Craniofac Surg.. 2013; 24:(2)602-604 https://doi.org/10.1097/scs.0b013e318267bcc5

Jankovic J, Brin MF. Therapeutic uses of botulinum toxin.. N Engl J Med.. 1991; 324:(17)1186-1194 https://doi.org/10.1056/nejm199104253241707

Jandhyala R. Impact of botulinum toxin a on the quality of life of subjects following treatment of facial lines.. J Clin Aesthet Dermatol.. 2013; 6:(9)41-45

Botulinum toxin overview.. 2010. http://tiny.cc/cii6ew (accessed 3 November 2020)

Lee JH, Park JH, Lee SK Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A.. J Dermatolog Treat.. 2014; 25:(4)326-330 https://doi.org/10.3109/09546634.2013.769041

Levy PM. Neurotoxins: current concepts in cosmetic use on the face and neck-jawline contouring/platysma bands/necklace lines.. Plast Reconstr Surg.. 2015; 136:(5)80-83s https://doi.org/10.1097/prs.0000000000001841

Lewis MB, Bowler PJ. Botulinum toxin cosmetic therapy correlates with a more positive mood.. J Cosmet Dermatol.. 2009; 8:(1)24-26 https://doi.org/10.1111/j.1473-2165.2009.00419.x

Liew S, Dart A. Nonsurgical reshaping of the lower face.. Aesthet Surg J.. 2008; 28:(3)251-257 https://doi.org/10.1016/j.asj.2008.03.003

Molina B, Grangier Y, Mole B Patient satisfaction after the treatment of glabellar lines with botulinum toxin type A (Speywood Unit): a multi-centre European observational study.. J Eur Acad Dermatol Venereol.. 2015; 29:(7)1382-1388 https://doi.org/10.1111/jdv.12881

Nigam PK, Nigam A. Botulinum toxin.. Indian J Dermatol.. 2010; 55:(1)8-14 https://doi.org/10.4103/0019-5154.60343

Pamphlett R. Early terminal and nodal sprouting of motor axons after botulinum toxin.. J Neurol Sci.. 1989; 92:(2–3)181-192 https://doi.org/10.1016/0022-510x(89)90135-4

Rohrich RJ, Rios JL, Smith PD, Gutowski KA. Neck rejuvenation revisited.. Plast Reconstr Surg.. 2006; 118:(5)1251-1263 https://doi.org/10.1097/01.prs.0000209406.80690.9f

Stanley EF, Drachman DB. Botulinum toxin blocks quantal but not non-quantal release of ACh at the neuromuscular junction.. Brain Res. 1983; 261:(1)172-175 https://doi.org/10.1016/0006-8993(83)91300-8

Wu DC, Fabi SG, Goldman MP. Neurotoxins: current concepts in cosmetic use on the face and necklower face.. Plast Reconstr Surg.. 2015; 136:76-79s https://doi.org/10.1097/prs.0000000000001750

The uses of botulinum toxin A in facial aesthetics

02 December 2020
Volume 9 · Issue 10

Abstract

The demand for non-surgical facial rejuvenation procedures is rising, and they are more popular than ever, with the aesthetic uses of botulinum toxin dramatically changing the landscape of facial rejuvenation. Botulinum toxin is a neurotoxin that works within cholinergic synapses present at neuromuscular endplates, preventing the transmission of neurotransmitters, such as acetylcholine, from nerves to muscles. This interference with nerve impulses leads to the muscles being temporarily weakened (paralysis). Botulinum toxin A was approved by the US Food and Drug Administration (FDA) for use in the glabella in 2002, followed by crow's feet in 2013 and then the forehead in 2017, with other aesthetic uses being classed as off-license. Botulinum toxin A yields good results in carefully selected patients, and a thorough consultation should always take place. Consultations should include management of expectations and the explanation that botulinum toxin A works on dynamic lines, rather than static lines. Treatment areas can be split into the upper face (glabellar, transverse forehead lines and lateral orbicularis oculi); mid face (bunny lines and perioral vertical lip lines); and lower face (masseter hypertrophy, mentalis, platysmal bands and gummy smile). Each patient should be assessed individually to determine individual anatomy, including the size, strength and location of muscles, with doses being adjusted accordingly.

With the increase in minimally invasive cosmetic surgical techniques and the rising popularity of non-surgical interventions such as dermal fillers and botulinum toxins, it is no surprise that the demand for facial rejuvenation procedures are more popular than ever. The aesthetic uses of botulinum toxin may have been discovered incidentally, but they have dramatically changed the landscape of facial rejuvenation.

The purpose of this article is to explore botulinum toxin as a medication, as well as the various indications, techniques and complications associated with its uses in facial aesthetics.

Botulinum toxin is the exotoxin of Clostridium botulinum, which is a spore-forming, gram-positive anaerobic bacterium (Kedlaya, 2010). In total, seven different serotypes are produced by Clostridium botulinum, namely A, B, C (C1, C2), D, E, F and G. Although structurally similar, each serotype varies in size and cellular mechanism, and also in its clinical usefulness. All serotypes bind to the same receptors, but target different proteins within the synapse. Additionally, each serotype differs in its potency and duration of effect.

Register now to continue reading

Thank you for visiting Journal of Aesthetic Nurses and reading some of our peer-reviewed resources for aesthetic nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • New content and clinical newsletter updates each month